Cited by 729Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

Open access

Lenz, Heinz-Josef, Van Cutsem, Eric, Luisa Limon, Maria, Wong, Ka Yeung Mark, Hendlisz, Alain, Aglietta, Massimo, García-Alfonso, Pilar, Neyns, Bart, Luppi, Gabriele, Cardin, Dana B., Dragovich, Tomislav, Shah, Usman, Abdullaev, Sandzhar, Gricar, Joseph, Ledeine, Jean-Marie, Overman, Michael James, Lonardi, Sara·2022·Journal of Clinical Oncology

DOI 10.1200/jco.21.01015

Open this paper in CoChat — free account Open PDF

Abstract

PURPOSE: Nivolumab received US Food and Drug Administration approval as a single agent or in combination with ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) that progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan based on CheckMate 142. Presented are results of nivolumab plus low-dose ipilimumab in the first-line therapy cohort from the phase II CheckMate 142 study. PATIENTS AND METHODS: Patients with no prior treatment in the metastatic setting for MSI-H/dMMR CRC were treated with nivolumab every 2 weeks plus low-dose ipilimumab every 6 weeks until disease progression. The primary end point was objective response rate (investigator assessment; RECIST v1.1). RESULTS: Median age of treated patients was 66 years (N = 45). Median follow-up was 29.0 months. Objective response rate and disease control rate were 69% (95% CI, 53 to 82) and 84% (95% CI, 70.5 to 93.5), respectively, with 13% complete response rate. Median duration of response was not reached; 74% of responders had ongoing responses at data cutoff. Median progression-free survival and median overall survival were not reached with minimum follow-up of 24.2 months (24-month rates, 74% and 79%, respectively). Clinical benefit was observed regardless of baseline demographic and tumor characteristics, including BRAF or KRAS mutation status. In a post hoc analysis, of 14 patients who discontinued treatment and did not receive subsequent therapy, 10 remained progression-free. Patient-reported outcomes were stable over the treatment period. Grade 3-4 treatment-related adverse events occurred in 22% of patients; 13% discontinued because of any-grade treatment-related adverse events. CONCLUSION: Nivolumab plus low-dose ipilimumab demonstrated robust and durable clinical benefit and was well tolerated as a first-line treatment for MSI-H/dMMR mCRC. Based on these promising data, randomized studies are warranted.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.21.01015

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Colorectal cancer statistics, 2017
Siegel, R. L., Miller, K. D., Fedewa, S. A., Ahnen, D. J., Meester, R. G. S., Barzi, A., & Jemal, A. (2017) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21395 · Cited by 3,807
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713

Flagged first, then by citations

Show all 30 references

Research works printed but not linked: 3

2020, Opdivo (nivolumab) Injection for Intravenous Use [prescribing information]
National Comprehensive Cancer Network, Colon Cancer (Version 2.2021)
National Comprehensive Cancer Network, Rectal Cancer (Version 1.2021)

Sorted by citations

Items 501–600 of 729

Risk and Management of Bowel Obstruction in Colorectal Cancer Patients Undergoing Immunotherapy: A Cross-Sectional Multicenter Study
Hong, Z., Xiao, B., Zheng, M., Yang, W., Zhu, L., Liang, G., Luo, Y., Tang, J., Mei, W.-J., Yu, J., et al. (2026) · ImmunoTargets and Therapy · doi:10.2147/itt.s563431 · Cited by 1
The clinical trial landscape of colorectal cancer liver metastases: profile analysis and target prediction
Li, M., Kai, J., Xu, Y., Zhu, S., Chen, Z., Zhao, H., & Zhu, W. (2026) · Clinical & Experimental Metastasis · doi:10.1007/s10585-026-10392-3 · Cited by 1
Disulfidptosis-related genes signature predicts prognosis and immune microenvironment in colon cancer
Jiang, W., Yang, H., Li, R., Li, Y., & Xia, S. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2026.1756041 · Cited by 1
Durable response to bispecific PD-1/ICOS antibody and ipilimumab in advanced microsatellite-stable colorectal cancer: a case report
Jung, S. A., Gates, K., Collins, H., Oyenuga, M., Emiloju, O. E., Hannan, L. M., & Alese, O. B. (2026) · Current Problems in Cancer Case Reports · doi:10.1016/j.cpccr.2026.100414 · Cited by 1
Hsa-miR-99a deficiency contributes to MSI-H colorectal cancer progression by activating the mTOR pathway and inducing Th1/Th2 imbalance
Yang, X., Zhang, T., Sun, H., Feng, H., & Song, D. E. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1796084 · Cited by 1
Therapeutic targeting of PD-1/PD-L1 and CTLA-4 in colorectal cancer: tumor-intrinsic and immune checkpoint signaling
Bhattacharya, S. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2655971 · Cited by 1
Current Status of the Diagnosis and Treatment of Mismatch Repair Deficient Colorectal Cancer
Bastin, D. J., Djedovic, V., Hyde, A. J., Goodwin, R. A., Asmis, T. R., & Vickers, M. M. (2026) · Biomedicines · doi:10.3390/biomedicines14051032 · Cited by 1
CD44‐Targeting Hydroxyapatite Nanoparticles (HAP) Induce Mitochondrial Dysfunction‐Driven PANoptosis and Immunogenic Cell Death (ICD) via Ca Overload in Colorectal Cancer
Xiao, Y.-Y., Yang, Y., Qiu, H., Yang, J., Liang, H., Jiang, Z., Tong, X., Li, Y., Huang, Q., Wu, J., et al. (2026) · Advanced Science · doi:10.1002/advs.75559 · Cited by 1
Immune microenvironment evolution across the serrated neoplasia pathway and its relevance to immunotherapy
Jin, C., Liu, H., Wu, Z., Hu, Y., Cui, Y., Guo, R., & Li, H. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1830436 · Cited by 1
Efficacy and risk analysis of monotherapy and dual immunotherapy in dMMR/MSI-H metastatic colorectal cancer: a meta-analysis based on randomized controlled trials
Wang, S., Gu, R., Lu, J., Wang, S., Tao, S., Zhang, X., Chen, L., An, Y., Gu, X., Li, Z., et al. (2026) · BMC Cancer · doi:10.1186/s12885-026-16033-y · Cited by 1
Dynamics of tumor ecosystems and microbiome in response to neoadjuvant ABFOLFOX treatment in patients with unresectable colorectal cancer with liver metastasis
Kim, W., Kim, J. E., Hong, Y. S., Hwang, D. W., Kim, J., Lee, J. S., Shin, J.-H., Kim, T. W., Nagarkar, D., Byrd, A. L., et al. (2026) · Genome Medicine · doi:10.1186/s13073-026-01680-4
Checkpoint inhibitors in microsatellite instability-high metastatic colorectal cancer: treatment strategies, specificities, and care management questions
André, T., Lonardi, S., Zaanan, A., Cohen, R., & Taı̈eb, J. (2026) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2026.100341 · Cited by 1
Self-citation
Microsatellite Phenotype as a Guide for Immunotherapy in Colorectal Cancer: Current Status and Future Perspectives
Koustas, E., Trifylli, E.-M., Oraiopoulos, V., Karamouzis, M. V., & Sarantis, P. (2026) · Genes · doi:10.3390/genes17060674 · Cited by 2
Mechanisms and Emerging Strategies to Overcome Immunotherapy Resistance in Cold Tumours of Colorectal Cancer
Zhu, X., Ge, B., & Wen, L. (2026) · OncoTargets and Therapy · doi:10.2147/ott.s621109 · Cited by 1
Nanomedicine delivery systems remodel the immunosuppressive microenvironment of colorectal cancer: synergistic strategies and mechanisms of targeted immune checkpoint inhibitors
Zhu, P., Han, A., & Quan, C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1882956 · Cited by 1
Dissecting immunosuppressive microenvironment in chemotherapy-resistant colorectal cancer through single-cell transcriptomic analysis
Xi, J., Li, Z., Liu, Y., Niu, W., Yu, B., Li, Z., & Wang, G. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102889 · Cited by 1
Evidence of endothelial anergy and T-cell exclusion in microsatellite stable colorectal liver metastases revealed through human hemi-liver perfusion and spatial transcriptomics
Wan, P. K.-T., Cheng, R., Johnson, D., Lee, C., Wu, S., Mian, A., Hazini, A., Moradi, S., Friesen, K., Caviezel, F., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02732-4 · Cited by 1
Replication stress in cancer: origins, consequences and therapeutic opportunities
Chen, J., & Zou, L. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00979-z · Cited by 2
Final results of nivolumab plus ipilimumab versus nivolumab or chemotherapy in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW
Lonardi, S., Lenz, H. J., Elez, E., Jensen, L. H., Cutsem, E. V., Touchefeu, Y., Garcia-Carbonero, R., Tougeron, D., Mendez, G. A., Schenker, M., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.09.009 · Cited by 1
Self-citation
News in immunotherapy of dMMR/MSI-H CRC
Liberko, M., & Soumarová, R. (2022) · Onkologie · doi:10.36290/xon.2022.023 · Cited by 1
Overview of predictive and prognostic biomarkers and their importance in developing a clinical pharmacology treatment plan in colorectal cancer patients
Crutcher, M. M., Snook, A. E., & Waldman, S. A. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2138339 · Cited by 1
Case report: Complete pathologic response with first-line immunotherapy combination in a young adult with massive liver dissemination of mismatch repair–deficient metastatic colorectal cancer: Immunological and molecular profiling
Bergamo, F., Santa, S. D., Loupakis, F., Cerma, K., Tosi, A., Grandis, M. C. D., Pietà, A. D., Gringeri, E., Angerilli, V., Ramondo, G., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.964219 · Cited by 1
Self-citation
Checkpointinhibitoren beim kolorektalen Karzinom – eine neue Ära?
Pox, C. P. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01495-0 · Cited by 1
Durable responses to tislelizumab plus fruquintinib and radiotherapy in refractory microsatellite stable metastatic colorectal cancer: a case report.
Zhao, W., & Huang, Z. (2023) · PubMed Central · Cited by 1
Case Report: Chemoimmunotherapy in microsatellite-instability-high advanced goblet cell carcinoma of the colon
Mutlu, A. U., Aytaç, E., Gülmez, M., Erdamar, S., & Özer, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1160586 · Cited by 1
The influence of gut microbiota on immunotherapy for Colorectal Cancer
de Melo, F. F. (2023) · Gastrointestinal Tract · doi:10.54844/git.2023.421 · Cited by 1
Double Duty: Complete Pathologic Response of Two Colonic Primaries with Mosaicism of a Novel MLH1 Mutation to Neoadjuvant Pembrolizumab
Preti, B. T. B., Schenkel, L. C., Cecchini, M. J., Romagnoli, T., Sanatani, M. S., French, K., Colquhoun, P. H. D., & Vincent, M. D. (2023) · Current Oncology · doi:10.3390/curroncol30100653 · Cited by 1
Surgical decision-making following neoadjuvant immunotherapy for dMMR rectal cancer; case reports and review of the literature
Nilbert, M. C., Eberhard, J., Engdahl, J., Edelhamre, M., Torle, F., Korkocic, D., & Jörgren, F. (2023) · Acta Oncologica · doi:10.1080/0284186x.2023.2281005 · Cited by 1
Immunotherapy in rectal cancer patients—a propensity score matched analysis of the National Cancer Database
Horesh, N., Emile, S. H., Freund, M. R., Garoufalia, Z., Gefen, R., Nagarajan, A., & Wexner, S. D. (2023) · International Journal of Colorectal Disease · doi:10.1007/s00384-023-04574-8 · Cited by 1
ADVANCES IN CANCER IMMUNOTHERAPY: A COMPREHENSIVE REVIEW OF CURRENT AND FUTURE APPROACHES IN THE TREATMENT OF SOLID AND HEMATOLOGIC TUMORS.
Specialist In Family And Community Medicine, C. D. S. T. A., Reinoso, G. P. G., Moscoso, N. P. C., Physician, U. C. D. E., Goyo, P. D. A., Physician, U. D. C., Rodríguez, B. S. P., Physician, U. D. L. A., Muñoz, J. V. U., & Physician, U. D. G. (2024) · International Journal of Medical Science and Dental Health · doi:10.55640/ijmsdh-10-02-16 · Cited by 1
Hepatitis inmunomediada: conceptos básicos y tratamiento
Velasco, J. A. V.-R., Calderón, D. K. T., Cerpa‐Cruz, S., Chávez, J. A. V., Martínez, J. F. U., García-Jiménez, E. S., Ledesma, J. M. A., Díaz‐González, Á., & Crespo, J. (2024) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2023.12.003 · Cited by 1
Immunotherapy-induced colitis in metastatic colorectal cancer: a systematic review and meta-analysis
Saowapa, S., Polpichai, N., Siladech, P., Wannaphut, C., Tanariyakul, M., Wattanachayakul, P., Bernal, D. A. O., Pleitez, H. J. G., & Tijani, L. (2024) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2024.2342723 · Cited by 1
Age-related outcomes in MSI/dMMR gastrointestinal cancers treated by immune checkpoint inhibitors and toxicity’s impact on efficacy: an immunoMSI cohort study
Mailly-Giacchetti, L., Colle, R., Samaille, T., Ataz, D. L.-T., Faucheux, L., Duval, A., André, T., & Cohen, R. (2024) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2024.100047 · Cited by 2
Microsatellite instability should not determine candidacy for cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion in patients with peritoneal metastases from colorectal cancer
Ruff, S. M., Hall, L. B., Choudry, H. A., Pingpank, J., Holtzman, M. P., Bartlett, D. L., Kim, A. C., & Ongchin, M. C. (2024) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2024.06.019 · Cited by 1
A pilot study on the detection of microsatellite instability using long mononucleotide repeats in solid tumors
Liu, T., Ho, C., Chen, Y.-J., Chen, P.-J., Chen, W., Lee, C., Chow, N., Huang, W., & Chen, Y. (2024) · Oncology Letters · doi:10.3892/ol.2024.14578 · Cited by 1
Efficacy of Combined PD-1 Inhibitor and Bevacizumab in Unresectable Liver Metastasis of MSI-H Colorectal Cancer: A Case Report
Wang, Q., Zhong, J., Wang, Y., Jun, B., Li, S., & Liu, Y. (2025) · American Journal of Case Reports · doi:10.12659/ajcr.946757 · Cited by 1
Tailored Approaches in the Treatment of Patients With Colorectal Cancer Harboring Tropomyosin Receptor Kinase Fusion and Microsatellite Instability-High: A Case Report and Literature Review
Kim, S., Itani, M., Liu, X., Sun, L., Krysiak, K., Fox, N., Firwana, B., Diffalha, S. A., Manne, U., Seeber, A., et al. (2025) · JCO Precision Oncology · doi:10.1200/po.24.00305 · Cited by 1
Anti-PD-1 treatment for MSI-H/MMRD tumors. A journey from genomics to transformative patient breakthroughs
Argilés, G., Arnold, D., & Cervantes, A. M. R. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.01.018 · Cited by 1
Real-world evaluation of treatment patterns and clinical outcomes in patients with BRAF-V600E metastatic colorectal cancer (mCRC) in Canada
Phillips, W. J., Marginean, H., Alrehaili, M., Abdelrahim, A. A., Asmis, T., Vickers, M., Yeung, B., Lo, B., & Goodwin, R. A. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.100896 · Cited by 2
Combination of immune checkpoint blockade in metastatic colorectal cancers with microsatellite instability: A new standard of care?
Randrian, V., & Rousseau, B. (2025) · Med · doi:10.1016/j.medj.2025.100636 · Cited by 1
Pembrolizumab versus bevacizumab plus modified FOLFOX6 in metastatic MSI-H/dMMR colorectal cancer: a multicenter retrospective study with CT evaluation
Chen, J., Yu, W., Xia, X., Zhao, Y., Tang, Q., Zhang, Y., Zhang, Y., Zhang, H., Zhang, Z., Zhang, X., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1570457 · Cited by 1
Evolución de la inmunoterapia en oncología a través del New England Journal of Medicine
Medina, M. L. (2024) · Medicina · doi:10.56050/01205498.2389 · Cited by 2
What are the optimal first-line therapies for patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer?
Taira, K., Kimura, A., Nakata, A., Tanaka, F., Nagami, Y., & Fujiwara, Y. (2023) · Annals of Palliative Medicine · doi:10.21037/apm-22-1391
Incorporation of Combination Immunotherapy into the Treatment Paradigms of Gastrointestinal Cancers
Kratz, J. D., William S. Middleton Veterans Administration Health System, M., & Uboha, N. V. (2023) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2023.19.2.1 · Cited by 1
Use of cytokine-induced killer cell therapy in colorectal cancer patients: a systematic review and meta-analysisPreprint
Li, C. M. Y., Tomita, Y., Dhakal, B., Li, R., Li, J., Drew, P. A., Price, T. J., Smith, E., Maddern, G. J., & Fenix, K. A. (2023) · medRxiv · doi:10.1101/2023.01.05.22283441 · Cited by 1
Immunological profiles in Lynch syndrome colorectal cancers are not specific to mismatch repair gene defectsPreprint
Helderman, N. C., Ijsselsteijn, M. E., Cabuta, M., van der Ploeg, M., van Wezel, T., Ahadova, A., Kloor, M., Morreau, H. M., Nielsen, M., & de Miranda, N. F. C. C. (2024) · medRxiv · doi:10.1101/2024.08.27.24311855 · Cited by 1
Neoadjuvant Immunotherapy in Operable Colon Cancer: Opportunities and Challenges
Dhimal, T., & Fleming, F. J. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-17043-z · Cited by 1
When new therapies arrive, we should think more: The unseen challenges of immunotherapy-induced remodeling
Wang, R. G. (2025) · World Journal of Clinical Cases · doi:10.12998/wjcc.v13.i33.113216 · Cited by 1
Justicia y medios de comunicación
Guillot, F. A. I. (1998) · Iuris: Actualidad y práctica del derecho
The mysteries of translation
Lesser, W. (2002) · In other words
Gemeinsame Stellungnahme der DGHO und DGVS zur Nutzenbewertung von Nivolumab (metastasiertes kolorektales Karzinom, dMMR oder MSI-H, vorbehandelte Patient*innen, Kombination mit Ipilimumab)
(2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1721-7018
Oncologie
Meyer, M., Chrysou, K., Stamatiou, A., Gilabert, M., Gómez, R. G. H., Latifyan, S., Masmoudi, S., Mederos, N., Perrinjaquet, C., Berthold, D., et al. (2022) · JMIG · doi:10.53738/revmed.2022.18.767.182
Medicina de precisión en cáncer colorrectal y gastroesofágico avanzado
Reyes, J. M. (2022) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2022.03.003
Kombinierte Checkpointblockade in der Erstlinie bei MSI-H/dMMR mCRC
Klein, F. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1781-7855
Organ Preservation in Colon Cancer: An Illustrative Case Report
Vora, K. B., Tolay, S., Parikh, A. R., & Chakrabarti, S. (2022) · Cureus · doi:10.7759/cureus.25351
Updates in the Treatment of Patients With Colorectal Cancer
Krishnamurthi, S. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.5013
2021 failures in drug therapy
Moiseyenko, F. V., Moiseenko, V. M., & Artemeva, E. (2022) · doi:10.31917/2301023
Retrospektive Analyse von an der Universitätsmedizin Göttingen (UMG) behandelten Patienten und Patientinnen mit kolorektalen Karzinomen im Zeitraum 2000 bis 2020 und Korrelation der klinischen Parameter mit Proteinanalysen
Rosen, L.-A. (2022) · doi:10.53846/goediss-9321
Kombinierte Checkpointblockade in der Erstlinie bei MSI-H/dMMR mCRC
(2022) · Gastroenterologie up2date · doi:10.1055/a-1792-0780
Impact of immunotherapy with pseudomonas serotip xv etanolic extract (Cantastim) on local recurrence and survival at 3 and 5 years in operated rectal cancer
Peşu, D. A., Zarnescu, E. C., Zărnescu, N. O., Sanda, N., Mihai, S. N., Sălăgeanu, A., & Neagu, Ş. I. (2022) · Romanian Medical Journal · doi:10.37897/rmj.2022.2.4
Editorial: ’All you need is immunotherapy’: a new treatment paradigm in sight for early-stage, mismatch repair-deficient/microsatellite instability high gastrointestinal cancers?
Sclafani, F., & Hendlisz, A. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000856
Self-citation
Immunotherapy for Colorectal Cancer in the Era of Precision Medicine
Sur, D. G., Gorzo, A., & Burz, C. C. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.105377
Diagnostik und Therapie des Kolonkarzinoms
Bisang, U., Zeitz, J., Groth, S., von Allmen, M., Schneider, P. M., & Samaras, P. (2022) · Schweizer Gastroenterologie · doi:10.1007/s43472-022-00081-3
Cellular Heterogeneity during Metastatic Colonization of Colorectal Cancer
Heinz, M. C. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/1556
Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials
Wei, X., Zhang, Y., Zhao, H., Fang, W., Luo, H., Qiu, M., He, M.-M., Zou, B., Xie, J., Jin, C., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac225 · Cited by 2
Therapie des Rektumkarzinoms und DNA-Mismatch-Reparatur-Defizienz mittels Immuncheckpoint-Inhibitoren
Lauscher, J. C. (2022) · coloproctology · doi:10.1007/s00053-022-00660-7
Recent Progress in Immunotherapy for Metastatic Colorectal Cancer
Kim, S., & Lee, J. (2022) · Journal of Digestive Cancer Research · doi:10.52927/jdcr.2022.10.2.65
Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients
Wahid, M., Mandal, R. K., Jawed, A., Alsulimani, A., Hashem, A. M., Harakeh, S., Hussain, A., Fagoonee, S., Pellicano, R., & Haque, S. (2023) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2022.2147683
Research Progress in Prognostic Markers of Immunotherapy for Non-Small Cell Lung Cancer
张, 科. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.131041
Skin affecting adverse events of immunotherapies for the treatment of malignancies
Kuzmanovszki, D., Kiss, N., Tóth, B., Tóth, V., Szakonyi, J., Hársing, J., Imrédi, E., Lőrincz, K. K., Kerner, T. Z., Doros, A., et al. (2022) · Bőrgyógyászati és Venerológiai Szemle · doi:10.7188/bvsz.2022.98.5.4
LRG1 is a novel HER3 ligand to promote growth in colorectal cancerPreprint
Rathore, M. G., Wright, M., Martin, D., Huang, W., Taylor, D. J., Miyagi, M., Feng, H., Li, Y., Wang, Z., Ellis, L. M., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.18.529070
Clinical significance of peripheral TCR repertoire profiling and individualized nomograms in patients with gastrointestinal cancer treated with anti-PD-1 antibodyPreprint
Wu, J., Yu, Y., Zhang, S., Zhang, P., Yu, S., Li, W., Wang, Y., Li, Q., Lu, B., Chen, L., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2551844/v1
PD-1 VS PD-L1 Inhibitors in Metastatic Cancers
Saravanan, S. (2022) · Journal of Student Research · doi:10.47611/jsrhs.v11i4.3695
Unresectable metastatic colorectal cancer in fit patients – a practical algorithm of treatment sequencing from the Brazilian Group of Gastrointestinal Tumours (GTG)
Peixoto, R. D., Coutinho, A. K., Prolla, G., Weschenfelder, R. F., & Riechelmann, R. P. (2023) · ecancermedicalscience · doi:10.3332/ecancer.2023.1544
Welchen Nutzen haben Immuntherapien beim kolorektalen Karzinom?
Pox, C. P. (2023) · Gastro-News · doi:10.1007/s15036-023-3283-2
Efficacy of First-Line Immunization and Targeted Therapy in Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-AnalysisPreprint
Zhou, Y., Gao, Y., Zhou, H., Fu, Y., Lin, Z., Shang, Y., Peng, S., Yang, C., & Ke, C. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4603279
Nivolumab in the treatment of pretreated patients with metastatic colorectal carcinoma with high microsatellite instability
Bencsiková, B. (2023) · Onkologie · doi:10.36290/xon.2023.054
Efficacy of First-Line Immunization and Targeted Therapy in Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-AnalysisPreprint
Zhou, Y., Gao, Y., Zhou, H., Fu, Y., Lin, Z., Shang, Y., Peng, S., Yang, C., & Ke, C. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4611835
Cancer Immunotherapy: A breakthrough in patient care
Kone, A.-S., Salah, N. E. I. I., Ghouzlani, A., & Badou, A. (2023) · Health Sciences · doi:10.56264/2658-865x.1087 · Cited by 1
LRG1 is a novel HER3 ligand and promotes growth in colorectal cancerPreprint
Wang, R., Rathore, M. G., Wright, M., Huang, W., Martin, D., Taylor, D. J., Miyagi, M., Tang, W., Feng, H., Li, Y., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3454771/v1
Research Advances on the Treatment of Liver Metastases from Early Stage Unresectable Colorectal Cancer
王, 承. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.13122626
Data from Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination
Simmons, K., Thomas, J. V., Ludford, K. T., Willis, J. A., Higbie, V. S., Raghav, K. P. S., Johnson, B., Dasari, A. N., Kee, B. K., Parseghian, C. M., et al. (2023) · doi:10.1158/2767-9764.c.6975005.v1
Self-citation
Efficacy of First-Line Immunization and Targeted Therapy in Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-AnalysisPreprint
Zhou, Y., Gao, Y., Zhou, H., Fu, Y., Wu, H., Lin, Z., Shang, Y., Peng, S., Yang, C., & Ke, C. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4750450
Laparoscopic complete mesocolic excision after neoadjuvant immunotherapy for advanced microsatellite instability high/deficient mismatch repair transverse colon cancer – a video vignette
Lian, Y., Duan, X., Hu, S., Han, M., & Yuan, W. (2024) · Colorectal Disease · doi:10.1111/codi.16965
Immunoediting on the Brink: Dynamic Relationship Between Tumor Genotype and Microenvironment as Determinant of Immunotherapy Effectiveness in an informative case report of Lynch SyndromePreprint
Zen, V., Cingarlini, S., Mafficini, A., Luchini, C., Mattiolo, P., Ciulla, C., Pavarana, M., Conciatori, F., Bazzichetto, C., Cucca, M., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4194990/v1
Disputes and Challenges of Immune Checkpoint Inhibitors in Gastrointestinal Cancers
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4910-0
PROGNOSTIC VALUE OF THE DENSITY OF TUMOR-INFILTRATING LYMPHOCYTES AND ITS ASSOCIATION WITH CLINICAL-MORPHOLOGICAL FEATURES OF COLON ADENOCARCINOMAS
Shkurupii, B., & Захарцева, Л. М. (2024) · Experimental Oncology · doi:10.15407/exp-oncology.2024.01.045
Lynch Syndrome
Edwards, P., & Monahan, K. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-59630-8_4
Immunotherapy for Gastrointestinal Malignancies
Zhu, M. (2024) · Springer eBooks · doi:10.1007/978-3-031-59475-5_12
SOX17 orchestrates immune evasion in early colorectal adenomas and cancers
Pei, B., Yang, H., & Zhou, F. (2024) · Immunology · doi:10.1111/imm.13831
Role of chemotherapy in colorectal cancers
Parisier, E. L., & Ocean, A. J. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780192863584.003.0016
Chemotherapie, gezielte Therapie und Immuntherapie des metastasierten kolorektalen Karzinoms
Richard, M., Koch, C., & Trojan, J. (2024) · Die Gastroenterologie · doi:10.1007/s11377-024-00815-6
Immunotherapeutic strategies for the treatment of colorectal cancer
Parisi, A., Arrichiello, G., Salati, M., & Petrillo, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13376-3.00003-4
An Evolving Landscape: New Therapies for Metastatic Colorectal Cancer
Mo, C., Chadha, B., & Kuang, C. (2024) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2024.08.003
Novel Therapies for Colorectal Cancers
Battaglia, M., Feldt, S. L., Marable, M., & Shergill, A. P. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1006035
Immunotherapy and immunomodulation in colorectal cancer treatment resistance
Damane, B. P., Mulaudzi, T. V., Montwedi, O. D., Mabeta, P., Kader, S., Leenders, W. P. J., & Dlamini, Z. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-33475-7.00013-5
Advances in immunotherapy for colorectal cancer
Lü, S., Rao, B., & Yang, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13827-0.00020-2
Role of Local Therapy for Metastatic Gastrointestinal Malignancies
Hui, C. (2024) · Digestive Disease Interventions · doi:10.1055/s-0044-1800822 · Cited by 1
Managing adverse effects of novel immunotherapies in pancreatic and colon cancers
Ahmed, Z., Ahmad, S. O., & Ahmad, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24742-2.00006-x · Cited by 1
Real-World Evaluation of Clinical Outcomes in Patients with Braf-V600e Metastatic Colorectal Cancer (Mcrc)Preprint
Phillips, W. J., Marginean, H., Alrehaili, M., Abdelrahim, A. A., Asmis, T., Vickers, M., Yeung, B., Lo, B., & Goodwin, R. A. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5120377

Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update.
Lenz, H., Lonardi, S., Zagonel, V., Cutsem, E. V., Limón, M. L., Wong, K. Y. M., Hendlisz, A., Aglietta, M., Alfonso, P. G., Neyns, B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.4_suppl.11 · Cited by 59
Self-citation
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
André, T., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.06.008 · Cited by 270
Self-citation
SO-27 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
André, T., Lonardi, S., Wong, K. Y. M., Lenz, H., Gelsomino, F., Aglietta, M., Morse, M. A., Cutsem, E. V., McDermott, R., Hill, A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.05.051 · Cited by 9
Self-citation
Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
Self-citation
Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update.
Lenz, H., Lonardi, S., Zagonel, V., Cutsem, E. V., Limón, M. L., Wong, M. K., Hendlisz, A., Aglietta, M., Alfonso, P. G., Neyns, B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.4040 · Cited by 43
Self-citation

See all

Authors: Lenz, H.-J., Van Cutsem, E., Luisa Limon, M., Wong, K. Y. M., Hendlisz, A., Aglietta, M., García-Alfonso, P., Neyns, B., Luppi, G., Cardin, D. B., Dragovich, T., Shah, U., Abdullaev, S., Gricar, J., Ledeine, J.-M., Overman, M. J., & Lonardi, S.
Affiliations: USC Norris Comprehensive Cancer Center (US)
University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium
Hospital Universitario Virgen del Rocio, Sevilla, Spain
Westmead Hospital (AU)
Institut Jules Bordet (BE)
Candiolo Cancer Institute (IT)
Hospital General Universitario Gregorio Marañón (ES)
Universitair Ziekenhuis Brussel (BE)
University of Modena and Reggio Emilia (IT)
Vanderbilt University (US)
Banner MD Anderson Cancer Center (US)
Lehigh Valley Cancer Institute, Allentown, PA
Bristol-Myers Squibb (United States) (US)
The University of Texas MD Anderson Cancer Center (US)
Istituto Oncologico Veneto (IT)
ORCID: Lenz, Heinz-Josef
Van Cutsem, Eric
Luisa Limon, Maria
Hendlisz, Alain
Aglietta, Massimo
Neyns, Bart
Cardin, Dana B.
Overman, Michael James
Lonardi, Sara
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2022-01-10
Volume: 40
Issue: 2
Pages: 161-170
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.21.01015
OpenAlex: W3206775306
Semantic Scholar: 2e81a9ea94ac646baf31c284ca8497f8b3df6f0e
Cited by: 728
References: 30
Citations by year: 2026: 125 · 2025: 148 · 2024: 182 · 2023: 173 · 2022: 93
FWCI: 41.26
Type: journal article
Language: en
Open access: green
biblio.vub.ac.be
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Lirias (submittedVersion)
Funders: Bristol-Myers Squibb
Agilent Technologies (PD-L1 IHC 28-8)
Ono Pharmaceutical
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords: nivolumab, ipilimumab, metastatic colorectal cancer, microsatellite instability-high, mismatch repair deficiency, first-line therapy, immune checkpoint inhibitors, combination immunotherapy, objective response rate, progression-free survival, treatment-related adverse events
MeSH terms: Ipilimumab, Nivolumab, Progression-Free Survival, Immune Checkpoint Inhibitors, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Time Factors, Colorectal Neoplasms, Disease Progression, Microsatellite Instability, DNA Mismatch Repair, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks